Pfizer Inc.

We’re honored to receive the Outstanding Corporate Partner Award from the American @LungAssociation. For decades, we’ve partnered with and sponsored the ALA to champion lung health—helping to make education and awareness efforts around pneumococcal pneumonia, COVID-19, and more…

We’re sharing new insights from our global Unmet Needs Survey at #EHA2025. Investigating the perspectives of people living with multiple myeloma and HCPs treating the disease to pinpoint critical gaps and barriers to optimal care. Read about our findings:…

Today we’ve announced the completion of a global, ex-China, licensing agreement with @3SBio Inc. for a next-generation bispecific antibody targeting PD-1 &VEGF under development for use in multiple solid tumor types. Learn more: on.pfizer.com/453yqbC

The @US_FDA has approved a once-monthly maintenance dosing option for patients with relapsed/refractory #MultipleMyeloma who have maintained a response after receiving 48 weeks of treatment, which can provide greater convenience: on.pfizer.com/3IwKpa3

How can scientists uncover clues hidden within cancer cells to develop more targeted cancer treatments? We challenged a Pfizer scientist to explain cancer biomarkers to friends, doctors, and scientists in episode 2 of Science Made Simple. Watch it here: on.pfizer.com/3ImVrii

We are pleased to announce positive topline results from our Phase 3 study in people living with #hemophilia A or B with inhibitors. Learn more: on.pfizer.com/4eljlGJ

Many people living with #IBD face delays in diagnosis often due to misattributed symptoms. In our Specialty Voices of Innovation series, Dr. Jessica Allegretti joins us to discuss the real barriers people face and how we can help close the gap. 🎥 Watch now:…

Lynce Lucas transforms her cancer diagnosis into advocacy with Pfizer. Read her story in @Essence: on.pfizer.com/4lnJoPW #CancerAwareness

At #AHSAM, we shared results from a Phase 4 trial, which is the first study exploring a gepant versus placebo for the acute treatment of migraine in adults who are unsuitable for triptans. Triptans are often the first prescription option for treating migraine. However, it’s…

What does our commitment to migraine care look like? At #AHSAM, we're presenting 14 abstracts featuring data across different populations of patients with migraine, including those who: ✔️ Are unsuitable for triptan use ✔️ Experience multiple migraine attacks per month ✔️ Are…

In our latest Dear Scientist episode, migraine patient & advocate Jenn sits down with Pfizer’s Chelsea Leroue, Migraine Medical Director. They explore why migraine disproportionately affects women and the urgent need for greater awareness and education. Catch the full story…

At #EHA2025 we’re joining the hematology community to share data from across our growing multi-modality hematology-oncology portfolio, building on 10+ yrs of experience advancing care and strengthening our commitment to patients with blood cancer. on.pfizer.com/3HBr5rR

Knowledge is power when it comes to navigating #ProstateCancer. This #MensHealthMonth, John, Dan, and Nick share what they learned throughout their own journeys with the disease so that those navigating it anew can learn from their insights. Learn more: bit.ly/45h5azN

.@llcoolj and Simone I. Smith faced cancer together. Now, they’ve partnered with Pfizer to encourage others to understand their risk factors and the importance of early detection. Read their story in @latimes: on.pfizer.com/4mH4HgF

📢It’s here! Pfizer’s 2024 #ImpactReport shows how we advanced science, access to care, and our commitment to responsible business growth. Because impact means more than breakthroughs—it’s about building a healthier world for all. 🔗 Read more: Pfizer.com/ImpactReport

Today at #ASCO25: Dr. Andrew Armstrong (@AArmstrongDuke) is sharing updates from our #ProstateCancer research program. Learn more: on.pfizer.com/3Hiaucz

One more birthday, one more moment, one more molecule – that's what the fight against cancer is all about. We're inspired to fight alongside the healthcare professionals working to give “one more” to patients. Explore our pipeline and resources at letsoutdocancer.com/hcp #ASCO25

With @Arvinas today at #ASCO25, and published in @NEJM, we are sharing detailed Phase 3 progression-free survival data in ESR1-mutant, ER+/HER2- advanced #BreastCancer. Read more: on.pfizer.com/3ZJ7JHj

A cancer breakthrough isn’t one moment. It’s decades of research, millions of data points, and resilience in the face of setbacks, all with the hope of challenging what’s possible. We’re not waiting for breakthroughs – we’re working to create them. Learn how:…

Today at #ASCO25, we presented pivotal progression-free survival and overall survival results from our Phase 3 study in patients with metastatic #ColorectalCancer (mCRC) with a BRAF V600E mutation. Learn more: on.pfizer.com/4jrMq4b